Why Is Vera Therapeutics Stock Trading Higher Today?
Vera Therapeutics Inc VERA announced 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). Data from the OLE show the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1),…
#veratherapeuticsinc #vera #ole #gdlga1 #hematuria #gdiga1 #upcr